ReviewDrugs2004
Basis for the management of drug-resistant Helicobacter pylori infection.
Review in Drugs, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis.Scientific reports · 2016Pooled it
- The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America.The American journal of gastroenterology · 2014Pooled it
- Pooled it
- Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.World journal of gastroenterology · 2008Trial
- Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin.World journal of gastroenterology · 2005Trial
- Green Chemistry Within the Circular Bioeconomy to Harness Chestnut Burr Extract's Synergistic Antimicrobial Activity AgainstMolecules (Basel, Switzerland) · 2025Article
- Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry.Infection · 2023Article
- Rifabutin as salvage therapy forWorld journal of gastroenterology · 2022Review
- Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry onJournal of clinical medicine · 2022Article
- Rifabutin for the Treatment ofPathogens (Basel, Switzerland) · 2020Review
- Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains.BMC gastroenterology · 2020Article
- Article
- Article
- The Helicobacter pylori eradication in the group receiving standard -dose and group continue taking amoxicillin for 4 weeks; a clinical trial study.Gastroenterology and hepatology from bed to bench · 2015Article
- Association between TNF-α and IL-1β genotypes vs Helicobacter pylori infection in Indonesia.World journal of gastroenterology · 2013Article
- Polysorbate 80 and Helicobacter pylori: a microbiological and ultrastructural study.BMC microbiology · 2012Article
- Anti-Helicobacter pylori potential of artemisinin and its derivatives.Antimicrobial agents and chemotherapy · 2012Article
- Transport kinetics and selectivity of HpUreI, the urea channel from Helicobacter pylori.Biochemistry · 2011Article
- Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.Digestive diseases and sciences · 2009Article
- A proteomic approach for the identification of bismuth-binding proteins in Helicobacter pylori.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery that most stomach diseases are a consequence of an Helicobacter pylori infection has completely changed the management of stomach diseases. Antibacterials are the treatment of choice in addition to proton pump inhibitors (PPIs) or ranitidine bismuth. We are now faced with the problem of antimicrobial resistance, which is the main cause of treatment failure. H. pylori acquires resistance essentially via point mutations, and today this phenomenon is found with most antibacterials. The most important resistance to consider is that to clarithromycin, since it is the first-choice antibacterial and clarithromycin resistance is highly clinically significant. Quadruple therapy or triple therapies with amoxicillin-metronidazole or tetracycline-metronidazole and a PPI or ranitidine bismuth can then be used despite a possible resistance to metronidazole if the strain is resistant to clarithromycin. Resistance to both clarithromycin and metronidazole may lead to the use of other combinations, i.e. amoxicillin-rifabutin, amoxicillin-levofloxacin or amoxicillin-furazolidone. Resistance to any of these drugs means their use must be avoided. In some instances, it may also be advisable to prescribe amoxicillin as the sole antibacterial, or to use a quadruple therapy with furazolidone instead of metronidazole. Although it is theoretically possible to cure a drug-resistant H. pylori infection, a practical limitation is the availability of the drugs in certain countries. Furthermore, the progressive increase in drug resistance warrants the need for new antibacterials in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.